The efficacy and safety of co-administration of fimasartan and rosuvastatin to patients with hypertension and dyslipidemia

Table 1 Inclusion criteria at randomization

Risk category	Cardiovascular risk factors^a	Randomization criteria
Risk category	Cardiovascular risk factors^a	LDL-cholesterol (mg/dL)	Averaged sitting SBP (mmHg)
Low risk	0 risk factors	≥160 and ≤ 250	≥140 and < 180
Moderate risk	1+ risk factors and 10 year risk < 10%	≥160 and ≤ 250
Moderate high risk	1+ risk factors and 10-year risk from 10% to 20%	≥130 and ≤ 250
High risk	CHD^b and CHD risk equivalent^c	≥100 and ≤ 250

^aRisk factors: include cigarette smoking, hypertension (BP ≥ 140/90 mm Hg or on antihypertensive medication), low HDL cholesterol (<40 mg/dL), family history of premature CHD (CHD in male first-degree relative < 55 years of age; CHD in female first-degree relative < 65 years of age), and age (men ≥ 45 years; women ≥ 55 years)
^bCHD (coronary heart disease) includes history of myocardial infarction, unstable angina, stable angina, coronary artery procedures (angioplasty or bypass surgery), or evidence of clinically significant myocardial ischemia
^cCHD (coronary heart disease) risk equivalents include clinical manifestations of noncoronary forms of atherosclerotic disease (peripheral arterial disease, abdominal aortic aneurysm, and carotid artery disease [transient ischemic attacks or stroke of carotid origin or > 50% obstruction of a carotid artery]), diabetes, and 2+ risk factors with 10-year risk for hard CHD > 20%

ISSN: 2050-6511